Overactive Bladder Clinical Trial
Official title:
"Transcutaneous Tibial Nerve Stimulation as a Conservative Treatment for Overactive Bladder Dysfunction -A Randomised Controlled Trial Comparing Home Versus Hospital Based Treatment"
Comparison of home versus hospital Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS).
TPTNS has been shown to be an effective treatment of overactive bladder in hospital. We aim
to see if this effect is replicated at home.
80 patients will be recruited, 40 into each arm.
Inclusion criteria:
1. Women aged ≥18 years
2. Clinical diagnosis of Overactive Bladder (OAB)
3. Post-void residual urine volume of < 100ml
4. Able to do questionnaires
5. Able to consent and willing to participate
Exclusion Criteria
1. Cardiac pacemaker in situ
2. Leg ulcer/skin condition affecting both lower legs
3. Diagnosed peripheral vascular disease
4. Absent sensation at the electrode site
5. Current Urinary Tract Infection (UTI) - must be treated with appropriate antibiotics as
per the unit protocol prior to commencing study
6. Pregnancy
7. Previous Percutaneous Tibial Nerve Stimulation (PTNS) /Sacral Nerve Stimulation (SNS)
course
8. Previous intravesical botox treatment
9. Unable to complete questionnaires
TPTNS will be taught to the home group and delivered to the participants in the hospital
group in individual appointments: 12 treatment sessions of 30 minutes duration, delivered
twice weekly over a 6 week period. Two surface electrodes are applied to the right ankle.
These electrodes are attached to an electrical stimulator, programmed to safely deliver
electric pulses.
On completion of 6 sessions, all participants will be contacted and asked to do a Patient
Global Impression of Improvement Scale (PGIIS) and Patient Perception of Bladder Condition
(PPBC). After 12 sessions (the final treatment session) all participants will be reviewed by
the investigators in the hospital and the outcome measures repeated. Participants receiving
home treatment will be posted out a 3 day bladder diary to complete. At this point the
participants receiving home treatment will return the machine. All participants will complete
and return a 72-hour bladder diary and validated questionnaires routinely used at the study
centre to measure lower urinary tract symptoms - The International Consultation of
Incontinence Modular Questionnaire - Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) long
form, the International Consultation of Incontinence Modular Questionnaire - Urinary
Incontinence questionnaire (ICIQ-UI short-form. The Hospital Anxiety and Depression Scale
(HADS) and the European Quality of Life - 5D Questionnaire (EQ-5D) will also be measured.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
| Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
| Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
| Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
| Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
| Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
| Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
| Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
| Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
| Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
| Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
| Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
| Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
| Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
| Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
| Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
| Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
| Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
| Completed |
NCT02667470 -
Reproducibility Study of OABSS and Its Response to Treatment
|
Phase 4 | |
| Completed |
NCT00910520 -
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
|
Phase 3 |